Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition-Reference-Cited by-同舟云学术

Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition

Published:2022-11 Issue: Volume: Page:
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Xie Yaochen,Zhou Qian,He Qiaojun,Wang Xiaoyi,Wang Jincheng^ORCID

Funder

China Postdoctoral Science Foundation

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference205 articles.

1. Diagnosis and classification of diabetes mellitus;Diabetes Care,2013

2. Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes;Packer;JACC Heart Fail,2021

3. Inflammatory targets in diabetic nephropathy;Donate-Correa;J Clin Med,2020

4. Definitions and criteria for diabetic foot disease;van Netten;Diabetes Metab Res Rev,2020

5. Social determinants of health and diabetes: a scientific review;Hill-Briggs;Diabetes Care,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional effects and mechanisms of Phyllanthus emblica fruit and gallic acid on metabolic diseases: Experimental evidence and clinical perspectives;Food Bioscience;2024-06

2. Computation assisted chemical study of photo-induced late-stage skeleton transformation of marine natural products towards new scaffolds with biological functions;Chinese Chemical Letters;2024-06

3. Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review;International Journal of Endocrinology;2024-02-13

4. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials;Metabolism;2023-12

5. A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations;Expert Opinion on Drug Metabolism & Toxicology;2023-11-26